biguanides has been researched along with Ovarian Neoplasms in 3 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Olaparib is a PARP inhibitor approved for maintenance therapy following platinum-based chemotherapy." | 1.56 | Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail. ( Amin, O; Baloch, T; Bithras, J; Kessous, R; Kogan, L; Laskov, I; López-Ozuna, VM; Wang, Q; Yasmeen, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| López-Ozuna, VM | 1 |
| Baloch, T | 1 |
| Bithras, J | 1 |
| Amin, O | 1 |
| Kessous, R | 1 |
| Kogan, L | 1 |
| Laskov, I | 1 |
| Yasmeen, A | 2 |
| Kenny, HA | 1 |
| Lal-Nag, M | 1 |
| White, EA | 1 |
| Shen, M | 1 |
| Chiang, CY | 1 |
| Mitra, AK | 1 |
| Zhang, Y | 1 |
| Curtis, M | 1 |
| Schryver, EM | 1 |
| Bettis, S | 1 |
| Jadhav, A | 1 |
| Boxer, MB | 1 |
| Li, Z | 1 |
| Ferrer, M | 1 |
| Lengyel, E | 1 |
| Segal, ED | 1 |
| Beauchamp, MC | 1 |
| Rosenblatt, J | 1 |
| Pollak, M | 1 |
| Gotlieb, WH | 1 |
3 other studies available for biguanides and Ovarian Neoplasms
| Article | Year |
|---|---|
Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biguanides; Carcinogenesis; Cell Line, Tumor; Cell M | 2020 |
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.
Topics: Animals; Antineoplastic Agents; Benzophenanthridines; Biguanides; Cantharidin; Cell Adhesion; Cell M | 2015 |
Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.
Topics: Adenylate Kinase; Antineoplastic Agents; Biguanides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fe | 2011 |